H E R Z I N G U N I V E R S I T Y · G R A D U AT E N U R S I N G · E X A M I N AT I O N
DOCUMENT
NU 627 EXAM 4
Advanced Pharmacology
for Nurse Practitioners
Actual Questions and Answers | 2026/2027 Updated |
With Complete Solutions — Herzing. Seventy-five
verified questions with comprehensive
pharmacotherapeutic rationales across endocrine,
neuropsychiatric, anti-infective, cardiovascular, and
pain pharmacology.
NU 627 — ADVANCED PHARMACOLOGY FOR NURSE
PRACTITIONERS
Aligned with 2026-2027 Herzing University NU 627 curriculum standards ·
Five sections · 75 questions · Verified answers with complete solutions
EXAM 4 · QUESTIONS 1–75 · 2026/2027 EDITION
,HERZING UNIVERSITY | GRADUATE NURSING | ADVANCED PHARMACOLOGY FOR NURSE PRACTITIONERS
NU 627 EXAM 4
Actual Questions and Answers | 2026/2027 Updated | With Complete Solutions - Herzing
75 questions with verified answers and comprehensive pharmacotherapeutic rationales | Five content sections aligned with
2026-2027 Herzing NU 627 curriculum standards | Cognitive mix: 25 percent recall, 55 percent application, 20 percent
analysis | Format: 80 percent scenario-based, 20 percent direct recall
SECTION 1: Endocrine Pharmacology
Questions 1-18 - Diabetes Management, Thyroid Disorders, Adrenal Disorders, and Metabolic Syndrome - Cognitive
level: applied analysis of pharmacotherapeutics
Q1: A 58-year-old woman with type 2 diabetes takes insulin glargine 24 units at bedtime plus
mealtime coverage. She asks which insulin she should inject immediately before breakfast, within
10 minutes of starting her meal. Which insulin has the pharmacokinetic profile most appropriate for
pre-meal dosing without requiring a 30-minute delay?
A. Regular insulin (Humulin R), because its 30-minute onset matches meal absorption
B. NPH insulin, because its intermediate peak covers postprandial glucose excursions
C. Insulin lispro (Humalog), because its 10-15 minute onset allows dosing immediately before
meals [CORRECT]
D. Insulin detemir (Levemir), because its prolonged duration provides continuous mealtime
coverage
Correct Answer: C
Rationale: Insulin lispro is a rapid-acting analog with an onset of approximately 10-15 minutes, a peak at
1-2 hours, and a duration of 3-5 hours, which aligns precisely with postprandial glucose excursions and
permits injection immediately before eating. Regular insulin must be administered about 30 minutes
before the meal because its hexameric structure delays subcutaneous absorption, so option A would require
the exact delay the patient wants to avoid. NPH peaks at 4-8 hours and its overlapping activity makes
immediate pre-meal use unpredictable with elevated hypoglycemia risk between meals. Detemir is a
long-acting basal insulin with a relatively peakless profile and is never an appropriate mealtime agent;
substituting it would leave prandial excursions untreated.
1
,NU 627 EXAM 4 | Advanced Pharmacology for Nurse Practitioners | 2026/2027 Edition
Q2: A 62-year-old man with type 2 diabetes and diabetic nephropathy has an eGFR of 26
mL/min/1.73 m2. He currently takes metformin 1000 mg twice daily. His A1c is 8.4 percent. What
is the most appropriate pharmacologic recommendation?
A. Discontinue metformin because an eGFR below 30 mL/min/1.73 m2 is a contraindication
due to the risk of lactic acidosis [CORRECT]
B. Continue metformin at the current dose because metformin-associated lactic acidosis is
only a theoretical concern
C. Double the metformin dose to overcome reduced renal tubular secretion
D. Switch to glyburide, which has the best renal safety profile among oral agents
Correct Answer: A
Rationale: Metformin is eliminated unchanged by the kidneys, and current FDA labeling plus the 2026
ADA Standards of Care contraindicate its use when eGFR falls below 30 mL/min/1.73 m2 because drug
accumulation increases the risk of potentially fatal lactic acidosis; between 30 and 45 the drug should not
be initiated and usually the dose is reduced. Doubling the dose at this eGFR would compound
accumulation and toxicity, so option C is the inverse of safe practice. Glyburide is actually among the
worst choices in advanced CKD because its active metabolites are renally cleared and produce prolonged,
severe hypoglycemia, a finding reflected on the Beers list. Appropriate alternatives for this patient include
a renally dosed DPP-4 inhibitor, an SGLT2 inhibitor for nephroprotection if eGFR permits initiation, a
GLP-1 receptor agonist, or basal insulin.
Q3: A 54-year-old woman taking empagliflozin for type 2 diabetes presents with two days of
nausea, vomiting, and malaise. Her capillary glucose is 210 mg/dL, urine ketones are large, and labs
show a high anion gap metabolic acidosis. She takes no other diabetes medications and has no
insulin exposure. What is the most likely explanation?
A. Severe hypoglycemia caused by SGLT2 inhibitor augmentation of insulin secretion
B. Classic diabetic ketoacidosis caused by SGLT2 inhibitor-induced absolute insulin
deficiency
C. Metformin-associated lactic acidosis despite the absence of metformin exposure
D. Euglycemic diabetic ketoacidosis, a recognized adverse effect of SGLT2 inhibitors
[CORRECT]
Correct Answer: D
Rationale: SGLT2 inhibitors shift glucose handling to urinary excretion and increase glucagon, which can
precipitate ketoacidosis with glucose values often below 250 mg/dL, masking the diagnosis; the FDA
issued a boxed-warning-level drug safety communication for euglycemic DKA in 2015 and the condition
remains emphasized in the 2026 ADA Standards. Recognition is critical because therapy requires holding
the SGLT2 inhibitor and treating with the standard DKA protocol of fluids, insulin, and potassium
replacement. Hypoglycemia is mechanistically implausible because SGLT2 inhibition is
insulin-independent and carries low intrinsic hypoglycemia risk. The acidosis is ketoacidosis rather than
lactic acidosis, and the patient has no metformin exposure, eliminating option C.
2
, NU 627 EXAM 4 | Advanced Pharmacology for Nurse Practitioners | 2026/2027 Edition
Q4: A 49-year-old man with type 2 diabetes on metformin monotherapy has an A1c of 8.9 percent
and a BMI of 38 kg/m2. He has nonalcoholic fatty liver disease, has no personal or family history of
medullary thyroid carcinoma or MEN2, and is highly motivated to lose weight. Which add-on agent
best meets his goals?
A. Pioglitazone, because it improves insulin sensitivity and reliably reduces weight
B. Semaglutide, a GLP-1 receptor agonist that promotes substantial weight loss and
cardiovascular risk reduction [CORRECT]
C. Glipizide, because insulin secretion stimulation produces durable weight loss
D. Sitagliptin, because DPP-4 inhibition produces substantial and sustained weight reduction
Correct Answer: B
Rationale: GLP-1 receptor agonists such as semaglutide produce 5-15 percent body weight reduction,
improve A1c, and demonstrate cardiovascular benefit (SUSTAIN-6), and the ADA Standards of Care
preferentially recommend GLP-1 receptor agonists or dual GIP/GLP-1 agonists such as tirzepatide in
patients with obesity. The absence of medullary thyroid carcinoma or MEN2 history satisfies the key
contraindication screening before initiation. Pioglitazone causes weight gain, fluid retention, and is
contraindicated in symptomatic heart failure, making it a poor match for a BMI of 38. Sulfonylureas cause
weight gain and hypoglycemia, while DPP-4 inhibitors are essentially weight-neutral rather than
weight-reducing, so neither achieves the patient's primary goal.
Q5: An 81-year-old woman with type 2 diabetes and CKD stage 3a is brought to the emergency
department with confusion and a capillary glucose of 46 mg/dL. She takes glyburide 10 mg daily.
After acute treatment, what is the best long-term management of her diabetes regimen?
A. Continue glyburide at the same dose, since sulfonylurea hypoglycemia is dose-related and
expected
B. Switch to chlorpropamide, which provides a smoother pharmacokinetic profile in older
adults
C. Discontinue glyburide and transition to a lower-hypoglycemia-risk agent such as a renally
dosed DPP-4 inhibitor [CORRECT]
D. Add acarbose to each meal to blunt future sulfonylurea-induced hypoglycemia
Correct Answer: C
Rationale: Glyburide appears on the AGS Beers Criteria because its active metabolites are renally cleared,
producing prolonged and sometimes fatal hypoglycemia in older adults with reduced kidney function, so
the safest intervention is to remove it and use an agent such as a DPP-4 inhibitor (renally dosed), which is
weight-neutral with minimal hypoglycemia risk. Continuing the same dose after a documented severe
hypoglycemic event ignores the predictable recurrence risk. Chlorpropamide has an even longer half-life
and greater hypoglycemia liability, making it strictly contraindicated in geriatric practice. Acarbose delays
carbohydrate absorption but does nothing to prevent insulin-independent sulfonylurea-induced
hypoglycemia and cannot treat an episode once it occurs, since digestion of sucrose is blocked and glucose
must be used.
3
DOCUMENT
NU 627 EXAM 4
Advanced Pharmacology
for Nurse Practitioners
Actual Questions and Answers | 2026/2027 Updated |
With Complete Solutions — Herzing. Seventy-five
verified questions with comprehensive
pharmacotherapeutic rationales across endocrine,
neuropsychiatric, anti-infective, cardiovascular, and
pain pharmacology.
NU 627 — ADVANCED PHARMACOLOGY FOR NURSE
PRACTITIONERS
Aligned with 2026-2027 Herzing University NU 627 curriculum standards ·
Five sections · 75 questions · Verified answers with complete solutions
EXAM 4 · QUESTIONS 1–75 · 2026/2027 EDITION
,HERZING UNIVERSITY | GRADUATE NURSING | ADVANCED PHARMACOLOGY FOR NURSE PRACTITIONERS
NU 627 EXAM 4
Actual Questions and Answers | 2026/2027 Updated | With Complete Solutions - Herzing
75 questions with verified answers and comprehensive pharmacotherapeutic rationales | Five content sections aligned with
2026-2027 Herzing NU 627 curriculum standards | Cognitive mix: 25 percent recall, 55 percent application, 20 percent
analysis | Format: 80 percent scenario-based, 20 percent direct recall
SECTION 1: Endocrine Pharmacology
Questions 1-18 - Diabetes Management, Thyroid Disorders, Adrenal Disorders, and Metabolic Syndrome - Cognitive
level: applied analysis of pharmacotherapeutics
Q1: A 58-year-old woman with type 2 diabetes takes insulin glargine 24 units at bedtime plus
mealtime coverage. She asks which insulin she should inject immediately before breakfast, within
10 minutes of starting her meal. Which insulin has the pharmacokinetic profile most appropriate for
pre-meal dosing without requiring a 30-minute delay?
A. Regular insulin (Humulin R), because its 30-minute onset matches meal absorption
B. NPH insulin, because its intermediate peak covers postprandial glucose excursions
C. Insulin lispro (Humalog), because its 10-15 minute onset allows dosing immediately before
meals [CORRECT]
D. Insulin detemir (Levemir), because its prolonged duration provides continuous mealtime
coverage
Correct Answer: C
Rationale: Insulin lispro is a rapid-acting analog with an onset of approximately 10-15 minutes, a peak at
1-2 hours, and a duration of 3-5 hours, which aligns precisely with postprandial glucose excursions and
permits injection immediately before eating. Regular insulin must be administered about 30 minutes
before the meal because its hexameric structure delays subcutaneous absorption, so option A would require
the exact delay the patient wants to avoid. NPH peaks at 4-8 hours and its overlapping activity makes
immediate pre-meal use unpredictable with elevated hypoglycemia risk between meals. Detemir is a
long-acting basal insulin with a relatively peakless profile and is never an appropriate mealtime agent;
substituting it would leave prandial excursions untreated.
1
,NU 627 EXAM 4 | Advanced Pharmacology for Nurse Practitioners | 2026/2027 Edition
Q2: A 62-year-old man with type 2 diabetes and diabetic nephropathy has an eGFR of 26
mL/min/1.73 m2. He currently takes metformin 1000 mg twice daily. His A1c is 8.4 percent. What
is the most appropriate pharmacologic recommendation?
A. Discontinue metformin because an eGFR below 30 mL/min/1.73 m2 is a contraindication
due to the risk of lactic acidosis [CORRECT]
B. Continue metformin at the current dose because metformin-associated lactic acidosis is
only a theoretical concern
C. Double the metformin dose to overcome reduced renal tubular secretion
D. Switch to glyburide, which has the best renal safety profile among oral agents
Correct Answer: A
Rationale: Metformin is eliminated unchanged by the kidneys, and current FDA labeling plus the 2026
ADA Standards of Care contraindicate its use when eGFR falls below 30 mL/min/1.73 m2 because drug
accumulation increases the risk of potentially fatal lactic acidosis; between 30 and 45 the drug should not
be initiated and usually the dose is reduced. Doubling the dose at this eGFR would compound
accumulation and toxicity, so option C is the inverse of safe practice. Glyburide is actually among the
worst choices in advanced CKD because its active metabolites are renally cleared and produce prolonged,
severe hypoglycemia, a finding reflected on the Beers list. Appropriate alternatives for this patient include
a renally dosed DPP-4 inhibitor, an SGLT2 inhibitor for nephroprotection if eGFR permits initiation, a
GLP-1 receptor agonist, or basal insulin.
Q3: A 54-year-old woman taking empagliflozin for type 2 diabetes presents with two days of
nausea, vomiting, and malaise. Her capillary glucose is 210 mg/dL, urine ketones are large, and labs
show a high anion gap metabolic acidosis. She takes no other diabetes medications and has no
insulin exposure. What is the most likely explanation?
A. Severe hypoglycemia caused by SGLT2 inhibitor augmentation of insulin secretion
B. Classic diabetic ketoacidosis caused by SGLT2 inhibitor-induced absolute insulin
deficiency
C. Metformin-associated lactic acidosis despite the absence of metformin exposure
D. Euglycemic diabetic ketoacidosis, a recognized adverse effect of SGLT2 inhibitors
[CORRECT]
Correct Answer: D
Rationale: SGLT2 inhibitors shift glucose handling to urinary excretion and increase glucagon, which can
precipitate ketoacidosis with glucose values often below 250 mg/dL, masking the diagnosis; the FDA
issued a boxed-warning-level drug safety communication for euglycemic DKA in 2015 and the condition
remains emphasized in the 2026 ADA Standards. Recognition is critical because therapy requires holding
the SGLT2 inhibitor and treating with the standard DKA protocol of fluids, insulin, and potassium
replacement. Hypoglycemia is mechanistically implausible because SGLT2 inhibition is
insulin-independent and carries low intrinsic hypoglycemia risk. The acidosis is ketoacidosis rather than
lactic acidosis, and the patient has no metformin exposure, eliminating option C.
2
, NU 627 EXAM 4 | Advanced Pharmacology for Nurse Practitioners | 2026/2027 Edition
Q4: A 49-year-old man with type 2 diabetes on metformin monotherapy has an A1c of 8.9 percent
and a BMI of 38 kg/m2. He has nonalcoholic fatty liver disease, has no personal or family history of
medullary thyroid carcinoma or MEN2, and is highly motivated to lose weight. Which add-on agent
best meets his goals?
A. Pioglitazone, because it improves insulin sensitivity and reliably reduces weight
B. Semaglutide, a GLP-1 receptor agonist that promotes substantial weight loss and
cardiovascular risk reduction [CORRECT]
C. Glipizide, because insulin secretion stimulation produces durable weight loss
D. Sitagliptin, because DPP-4 inhibition produces substantial and sustained weight reduction
Correct Answer: B
Rationale: GLP-1 receptor agonists such as semaglutide produce 5-15 percent body weight reduction,
improve A1c, and demonstrate cardiovascular benefit (SUSTAIN-6), and the ADA Standards of Care
preferentially recommend GLP-1 receptor agonists or dual GIP/GLP-1 agonists such as tirzepatide in
patients with obesity. The absence of medullary thyroid carcinoma or MEN2 history satisfies the key
contraindication screening before initiation. Pioglitazone causes weight gain, fluid retention, and is
contraindicated in symptomatic heart failure, making it a poor match for a BMI of 38. Sulfonylureas cause
weight gain and hypoglycemia, while DPP-4 inhibitors are essentially weight-neutral rather than
weight-reducing, so neither achieves the patient's primary goal.
Q5: An 81-year-old woman with type 2 diabetes and CKD stage 3a is brought to the emergency
department with confusion and a capillary glucose of 46 mg/dL. She takes glyburide 10 mg daily.
After acute treatment, what is the best long-term management of her diabetes regimen?
A. Continue glyburide at the same dose, since sulfonylurea hypoglycemia is dose-related and
expected
B. Switch to chlorpropamide, which provides a smoother pharmacokinetic profile in older
adults
C. Discontinue glyburide and transition to a lower-hypoglycemia-risk agent such as a renally
dosed DPP-4 inhibitor [CORRECT]
D. Add acarbose to each meal to blunt future sulfonylurea-induced hypoglycemia
Correct Answer: C
Rationale: Glyburide appears on the AGS Beers Criteria because its active metabolites are renally cleared,
producing prolonged and sometimes fatal hypoglycemia in older adults with reduced kidney function, so
the safest intervention is to remove it and use an agent such as a DPP-4 inhibitor (renally dosed), which is
weight-neutral with minimal hypoglycemia risk. Continuing the same dose after a documented severe
hypoglycemic event ignores the predictable recurrence risk. Chlorpropamide has an even longer half-life
and greater hypoglycemia liability, making it strictly contraindicated in geriatric practice. Acarbose delays
carbohydrate absorption but does nothing to prevent insulin-independent sulfonylurea-induced
hypoglycemia and cannot treat an episode once it occurs, since digestion of sucrose is blocked and glucose
must be used.
3
